280 related articles for article (PubMed ID: 12552124)
1. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk.
Paez-Pereda M; Giacomini D; Refojo D; Nagashima AC; Hopfner U; Grubler Y; Chervin A; Goldberg V; Goya R; Hentges ST; Low MJ; Holsboer F; Stalla GK; Arzt E
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1034-9. PubMed ID: 12552124
[TBL] [Abstract][Full Text] [Related]
2. [New mechanisms involved in the pathogenesis of pituitary adenomas].
Giacomini D; Páez-Pereda M; Refojo D; Carbia Nagashima A; Chervin A; Goldberg V; Arzt E
Medicina (B Aires); 2003; 63(2):147-50. PubMed ID: 12793085
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor YY1 inhibits transforming growth factor beta- and bone morphogenetic protein-induced cell differentiation.
Kurisaki K; Kurisaki A; Valcourt U; Terentiev AA; Pardali K; Ten Dijke P; Heldin CH; Ericsson J; Moustakas A
Mol Cell Biol; 2003 Jul; 23(13):4494-510. PubMed ID: 12808092
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic protein-2 and -4 limit the number of enteric neurons but promote development of a TrkC-expressing neurotrophin-3-dependent subset.
Chalazonitis A; D'Autréaux F; Guha U; Pham TD; Faure C; Chen JJ; Roman D; Kan L; Rothman TP; Kessler JA; Gershon MD
J Neurosci; 2004 Apr; 24(17):4266-82. PubMed ID: 15115823
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein-2 (BMP-2) transactivates Dlx3 through Smad1 and Smad4: alternative mode for Dlx3 induction in mouse keratinocytes.
Park GT; Morasso MI
Nucleic Acids Res; 2002 Jan; 30(2):515-22. PubMed ID: 11788714
[TBL] [Abstract][Full Text] [Related]
6. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression in models of pituitary prolactin-producing tumoral cells.
Giacomini D; Haedo M; Gerez J; Druker J; Páez-Pereda M; Labeur M; Stalla GK; Arzt E
Horm Res; 2009 Apr; 71 Suppl 2():88-94. PubMed ID: 19407504
[TBL] [Abstract][Full Text] [Related]
8. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells.
Zhou S; Turgeman G; Harris SE; Leitman DC; Komm BS; Bodine PV; Gazit D
Mol Endocrinol; 2003 Jan; 17(1):56-66. PubMed ID: 12511606
[TBL] [Abstract][Full Text] [Related]
9. Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis.
Katagiri T; Imada M; Yanai T; Suda T; Takahashi N; Kamijo R
Genes Cells; 2002 Sep; 7(9):949-60. PubMed ID: 12296825
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action.
Giacomini D; Páez-Pereda M; Theodoropoulou M; Labeur M; Refojo D; Gerez J; Chervin A; Berner S; Losa M; Buchfelder M; Renner U; Stalla GK; Arzt E
Endocrinology; 2006 Jan; 147(1):247-56. PubMed ID: 16195406
[TBL] [Abstract][Full Text] [Related]
11. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon.
Hardwick JC; Van Den Brink GR; Bleuming SA; Ballester I; Van Den Brande JM; Keller JJ; Offerhaus GJ; Van Deventer SJ; Peppelenbosch MP
Gastroenterology; 2004 Jan; 126(1):111-21. PubMed ID: 14699493
[TBL] [Abstract][Full Text] [Related]
13. Pituitary tumors: cell type-specific roles for BMP-4.
Labeur M; Páez-Pereda M; Haedo M; Arzt E; Stalla GK
Mol Cell Endocrinol; 2010 Sep; 326(1-2):85-8. PubMed ID: 20398728
[TBL] [Abstract][Full Text] [Related]
14. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
15. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between bone morphogenetic protein and transforming growth factor-beta signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells.
Yew KH; Hembree M; Prasadan K; Preuett B; McFall C; Benjes C; Crowley A; Sharp S; Tulachan S; Mehta S; Tei E; Gittes G
J Biol Chem; 2005 Sep; 280(37):32209-17. PubMed ID: 16020542
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of estrogen and estrogen receptor antagonist, ICI 182 780, on the expression of calbindin-D9k in rat pituitary prolactinoma GH₃ cells.
Wang W; Knosp E; Tai G; Zhao Y; Liang Q; Guo Y
Int J Clin Exp Pathol; 2014; 7(12):8498-505. PubMed ID: 25674214
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors.
Langenfeld EM; Langenfeld J
Mol Cancer Res; 2004 Mar; 2(3):141-9. PubMed ID: 15037653
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
20. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.
Winkler DG; Yu C; Geoghegan JC; Ojala EW; Skonier JE; Shpektor D; Sutherland MK; Latham JA
J Biol Chem; 2004 Aug; 279(35):36293-8. PubMed ID: 15199066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
